Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer

Overview

Journal J Breast Cancer

Date 2018 Jul 3

PMID 29963107

Citations 38

Authors

Yunxuan Wang

Tieying Dong

Qijia Xuan

Hong Zhao

Ling Qin

Qingyuan Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: In this study, we aimed to evaluate lymphocyte-activation gene-3 (LAG-3) expression and its prognostic value in neoadjuvant-treated triple-negative breast cancer (TNBC).

Methods: LAG-3, programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and CD8 tumor-infiltrating lymphocyte (TILs) levels were examined using immunohistochemistry in 148 preand 114 post-neoadjuvant chemotherapy (NACT) specimens of human TNBC tissue. Correlations between expression levels and clinicopathological features were analyzed. Prognostic values for combined detection in TNBC following NACT were evaluated.

Results: In pre-NACT specimens, LAG-3 expression showed a significant association with pathological complete response (pCR, =0.038) and was correlated with PD-1 (<0.001) and PD-L1 (=0.008). In post-NACT specimens, high expression of LAG-3 showed significant effects on nodal status (=0.023) and PD-1 (<0.001). The expression of immune markers on TILs significantly increased following NACT. Multivariate analysis indicated that only nodal status (odds ratio [OR], 0.226; 95% confidence interval [CI], 0.079-0.644; =0.005) and high quantities of CD8TILs (OR, 3.186; 95% CI, 1.314-7.721; =0.010) are independent predictors of pCR. Nodal status (hazard ratio [HR], 2.666; 95% CI, 1.271-5.594; =0.010), CD8TILs (HR, 0.313; 95% CI, 0.139-0.705; =0.005), and the LAG-3-high/PD-L1-high group (HR, 2.829; 95% CI, 1.050-7.623; =0.040) provided prognostic values for patients with TNBC following NACT.

Conclusion: CD8TILs were sensitive predictive markers in response to NACT. High expression of LAG-3 in residual tissues, especially in combination with PD-L1, was associated with poor prognosis.

Citing Articles

Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.

Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F Med Oncol. 2024; 42(1):36.

PMID: 39719469 DOI: 10.1007/s12032-024-02588-y.

Detailed Profiling of the Tumor Microenvironment in Ethnic Breast Cancer, Using Tissue Microarrays and Multiplex Immunofluorescence.

Zaakouk M, Longworth A, Hunter K, Jiman S, Kearns D, El-Deftar M Int J Mol Sci. 2024; 25(12).

PMID: 38928207 PMC: 11203983. DOI: 10.3390/ijms25126501.

Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis.

Bahrin N, Matusin S, Mustapa A, Huat L, Perera S, Hamid M Syst Rev. 2024; 13(1):100.

PMID: 38576013 PMC: 10993489. DOI: 10.1186/s13643-024-02520-5.

Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer.

Wang J, Wang S, Zhang Y, Zhang W Front Immunol. 2024; 15:1329775.

PMID: 38390331 PMC: 10881671. DOI: 10.3389/fimmu.2024.1329775.

Immune checkpoint status and exhaustion-related phenotypes of CD8 T cells from the tumor-draining regional lymph nodes in breast cancer.

Yilmaz I, Tavukcuoglu E, Horzum U, Yilmaz K, Akinci M, Gulcelik M Cancer Med. 2023; 12(24):22196-22205.

PMID: 38069525 PMC: 10757146. DOI: 10.1002/cam4.6802.

References

He Y, Yu H, Rozeboom L, Rivard C, Ellison K, Dziadziuszko R . LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017; 12(5):814-823. DOI: 10.1016/j.jtho.2017.01.019. View

Muenst S, Soysal S, Gao F, Obermann E, Oertli D, Gillanders W . The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013; 139(3):667-76. PMC: 3885332. DOI: 10.1007/s10549-013-2581-3. View

Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini P . LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 2003; 63(10):2518-25. View

Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T . Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010; 107(17):7875-80. PMC: 2867907. DOI: 10.1073/pnas.1003345107. View

Mesnage S, Auguste A, Genestie C, Dunant A, Pain E, Drusch F . Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann Oncol. 2016; 28(3):651-657. DOI: 10.1093/annonc/mdw625. View

Fraser Symmans W, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-22. DOI: 10.1200/JCO.2007.10.6823. View

Waugh K, Leach S, Moore B, Bruno T, Buhrman J, Slansky J . Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J Immunol. 2016; 197(4):1477-88. PMC: 4976021. DOI: 10.4049/jimmunol.1600589. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Nguyen L, Ohashi P . Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2014; 15(1):45-56. DOI: 10.1038/nri3790. View

10.

Teng F, Meng X, Kong L, Mu D, Zhu H, Liu S . Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Transl Res. 2015; 166(6):721-732.e1. DOI: 10.1016/j.trsl.2015.06.019. View

11.

Caudle A, Yu T, Tucker S, Bedrosian I, Litton J, Gonzalez-Angulo A . Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012; 14(3):R83. PMC: 3446346. DOI: 10.1186/bcr3198. View

12.

Li F, Zhang Y, Jin G, Yao L, Wu D . Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett. 2012; 150(1-2):116-22. DOI: 10.1016/j.imlet.2012.12.004. View

13.

Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T . Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Res. 2015; 75(23):5034-45. DOI: 10.1158/0008-5472.CAN-14-3098. View

14.

Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I . Prognostic markers in triple-negative breast cancer. Cancer. 2006; 109(1):25-32. DOI: 10.1002/cncr.22381. View

15.

Song I, Heo S, Bang W, Park H, Park I, Kim Y . Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat. 2016; 49(2):399-407. PMC: 5398384. DOI: 10.4143/crt.2016.215. View

16.

Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y . PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer. 2016; 7(7):784-93. PMC: 4860794. DOI: 10.7150/jca.14549. View

17.

Golden E, Demaria S, Schiff P, Chachoua A, Formenti S . An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2014; 1(6):365-72. PMC: 3930458. DOI: 10.1158/2326-6066.CIR-13-0115. View

18.

Taube J, Young G, McMiller T, Chen S, Salas J, Pritchard T . Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clin Cancer Res. 2015; 21(17):3969-76. PMC: 4558237. DOI: 10.1158/1078-0432.CCR-15-0244. View

19.

Foy S, Sennino B, Dela Cruz T, Cote J, Gordon E, Kemp F . Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS One. 2016; 11(2):e0150084. PMC: 4765931. DOI: 10.1371/journal.pone.0150084. View

20.

Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134-44. PMC: 4126516. DOI: 10.1056/NEJMoa1305133. View